The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack

NCT ID: NCT02144831

Last Updated: 2022-05-27

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2018-10-31

Brief Summary

The primary goal of the research is to determine if 10 days of dual anti-platelet treatment is as effective as 30 days of similar treatment in the prevention of stroke, myocardial ischemia (MI) and death in patients with TIAs and minor stroke.

Detailed Description

Transient Ischemic Attacks (TIAs) are common, easily misdiagnosed, not investigated appropriately and are often harbingers of disabling strokes. A TIA is best defined as an episode of neurological dysfunction caused by focal ischemia that lasts for less than 24 hours (very often less than an hour). Minor stroke (NIHSS of <3) is often lumped together with TIAs. The distinction between minor ischemic stroke and TIA is unimportant in terms of prognosis. Numerous studies have shown that short-term risk of stroke is high after TIA and minor ischemic stroke, particularly in the first few days, even in patients treated with aspirin, the current standard of care. In patients with TIAs and minor stroke effective therapies can significantly reduce the overall burden of stroke if initiated immediately. The recently completed CHANCE study comprising more than 5000 patients with TIAs and minor stroke showed that a short course of combination antiplatelet medications (ASA+clopidogrel) for 3 weeks significantly reduced the 90-day risk of stroke when compared to ASA treatment.

There are three trials where patients with TIAs and minor strokes were treated early after onset of symptoms with combination treatment with clopidogrel and ASA versus ASA alone. FASTER was a pilot trial based in Canada (5). It evaluated clopidogrel (300 mg load and 75 mg/day afterwards) on a background of aspirin in patients presenting within 24 hours of a TIA or minor stroke. The trial enrolled 392 patients. The risk of stroke (ischemic or hemorrhagic) at 90 days was 11% in those treated with aspirin alone and 7% in those treated with clopidogrel and aspirin, a non-significant 36% relative risk reduction (RRR) in this pilot trial (p=0.19). There were two Intra cerebral hemorrhages(ICHs) and these were both in patients treated with clopidogrel and ASA.

The recently completed CHANCE trial (5170 patients enrolled within 24 hours of symptom-onset) from China showed that in patients with high-risk TIAs and minor strokes, there was a significant absolute reduction of early stroke at 90 days from 11.7 % to 8.2 % hazard ration (HR) 0.68, 95% Confidence interval (CI) 0.57-0.81; p<0.001) in patients treated with a combination of ASA and clopidogrel for 21 days compared to ASA alone (13). Similar to the EXPRESS study (3), most of the strokes developed in the initial days following the TIA. The observation that strokes occur very early, as is evident from EXPRESS and CHANCE suggests that perhaps the vascular pathology responsible for the events begins to heal rapidly once antiplatelet therapy is initiated. This allows for the possibility that shorter duration combination antiplatelet therapy may also be as effective as the 21 days treatment in CHANCE or the 30 days treatment in the NIH funded POINT trial. A prospective study that compares the outcome of stroke, MI or death at 90 days in patients treated with 10 days or 30 days of dual antiplatelet therapy will therefore be very useful. If the shorter duration dual antiplatelet therapy is as effective as the longer duration dual antiplatelet treatment, this will result in lower costs and the lower risk of side effects in stroke prevention in high-risk TIA patients.

Hypothesis:

The short duration use of dual antiplatelet agents for 10 days is as effective as a longer duration of 30 days or longer. The shorter duration treatment will however result in fewer hemorrhagic complications.

STUDY OBJECTIVES

The Primary Specific Aim of this randomized, multicenter clinical trial is to determine whether a 10 day course of treatment with clopidogrel 75 mg/day by mouth after a loading dose of 600 mg is as effective a similar treatment for 30 days in improving survival free from ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when subjects are randomized within 24 hours of time last known free of new ischemic symptoms in patients receiving aspirin 50-325 mg/day as the long-term antiplatelet therapy.

There will be several secondary aims of the study, including comparison of the risk of major and minor hemorrhage, the risk of recurrent TIAs or minor stroke at 10-day, 30-day and 90-day evaluations and the measuring severity of any stroke in the two arms in the 90 days of follow-up. The NIHSS will be used for assessment of the severity of the stroke.

Participation Centers During the course of the trial, approximately 10-15 sites will enroll approximately 1200 subjects with TIA or minor ischemic stroke. Before enrolling subjects into the study, all collaborating sites will obtain approval from local institutional review boards (IRBs), which will have access to all study documentation and educational materials.

Study Population The study will include both TIA and minor ischemic stroke. Neurological impairment at the time of enrollment is expected to be minimal since the deficits prompting diagnosis will have largely resolved. Vascular risk factors, including diabetes, hypertension, and coronary artery disease, are expected to be common.

Pregnant women will be excluded from the study because the safety of clopidogrel is not established in this population, and this drug may increase risk of harm to the fetus. Women at risk for pregnancy (see Exclusion Criteria) will also be excluded. No other vulnerable population will be excluded from the study.

TREATMENTS Study Drugs This randomized study is primarily designed to compare a clopidogrel/aspirin combination versus an aspirin alone regimen for 10 days versus 30 days. This is an open-label design. Patients and physicians will be aware of the study medications.

Aspirin tablets will be open label with the dose in a range 50-325 mg daily determined by the treating physician. A dose of 162 mg daily x 5 days, followed by 81 mg daily will be strongly recommended.

Clopidogrel treatment will be offered in the following manner:

Day 1: 8 tablets of clopidogrel 75 mg (loading dose of 600 mg) From D2 to D10 or D2 to D30: one tablet of clopidogrel 75 mg

All patients will be on ASA 50-325 for the 90 days until the final assessment. Assignment to a Treatment Group The randomization will take place locally. To keep the study simple, sequential subjects will be randomized to 10 days (even number recruitment) and 30 day (odd number recruitment). All centers will recruit competitively into the trial.

Conditions

Transient Ischemic Attacks; Minor Stroke

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

anti-thrombotic treatment

10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment

Group Type: ACTIVE_COMPARATOR

anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)

Intervention Type: DRUG

comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel

anti-thrombotic

30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment

Group Type: ACTIVE_COMPARATOR

anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)

Intervention Type: DRUG

comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel

Interventions

anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)

comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Neurologic deficit (based on history or exam) attributed to focal brain ischemia and EITHER:

High risk TIA: Complete resolution of the deficit at the time of randomization AND age, blood pressure, clinical features, duration of TIA and presence of diabetes (ABCD2) score >4 OR Minor ischemic stroke: residual deficit with NIHSS ≤3 at the time of randomization.

2. Ability to randomize within 24 hours of time last known free of new ischemic symptoms.

3. Head CT or MRI ruling out hemorrhage or other pathology, such as vascular malformation, tumor, or abscess, that could explain symptoms or contraindicate therapy.

4. Ability to tolerate aspirin at a dose of 50-325 mg/day.

Exclusion Criteria

1. TIA symptoms limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo.

2. In the judgment of the treating physician, a candidate for thrombolysis, endarterectomy or endovascular intervention, unless the subject declines both endarterectomy and endovascular intervention at the time of the evaluation for eligibility.

3. Receipt of any intravenous or intra-arterial thrombolysis within 1 week prior to index event.

4. Gastrointestinal bleed or major surgery within 3 months prior to index event. History of non-traumatic intracranial hemorrhage.

5. Clear indication for anticoagulation (e.g., warfarin, heparin) anticipated during the study period (atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state).

6. Qualifying ischemic event induced by angiography or surgery.

7. Severe non-cardiovascular comorbidity with life expectancy <3 months.

8. Contraindication to clopidogrel or aspirin:

• Known allergy
• Severe renal (serum creatinine >2 mg/dL) or hepatic insufficiency (prior or concurrent diagnosis, with international normalized ratio (INR)>1.5, or any resultant complication, such as variceal bleeding, encephalopathy, or icterus)
• Hemostatic disorder or systemic bleeding in the past 3 months
• Current thrombocytopenia (platelet count <100 x109/l) or neutropenia/granulocytopenia (<1 x109/l) o History of drug-induced hematologic or hepatic abnormalities

9. Anticipated requirement for long-term (>10 days) nonstudy antiplatelet drugs (eg, dipyridamole, clopidogrel, ticlopidine), or non steroidal anti inflammatory drugs (NSAIDs) affecting platelet function (such as prior vascular stent or arthritis).

10. Not willing or able to discontinue prohibited concomitant medications. Inability to swallow medications.

11. At risk for pregnancy: premenopausal or postmenopausal woman within 12 months of last menses without a negative pregnancy test or not committing to adequate birth control (e.g., oral contraceptive, two methods of barrier birth control, or abstinence).

12. Unavailability for follow-up. Signed and dated informed consent not obtained from patient.

Other neurological conditions that would complicate assessment of outcomes during follow-up.

Ongoing treatment in another study of an investigational therapy, or treatment in such a study within the last 7 days.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Alberta

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ashfaq Shuaib, MD FRCPC

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

University of Alberta Hospital

Edmonton, Alberta, Canada

Countries

Canada

Other Identifiers

MENA-TIA study

Identifier Type: -

Identifier Source: org_study_id